Showing 3661-3670 of 4164 results for "".
- Clinreg Consulting Services Appoints New President and Plans to Expand Consulting Teamhttps://modernod.com/news/clinreg-consulting-services-appoints-new-president-and-plans-to-expand-consulting-team/2476920/Clinreg Consulting Services, a provider of regulatory, clinical, statistical, data management, and quality consulting services, announced the appointment of Lee Kramm, MD, MSE, as President and plans to expand its con
- Nicox Completes Enrollment of NCX 4251 Phase 2 Trial with Topline Results on Track for Q4 2019https://modernod.com/news/nicox-completes-enrolment-of-ncx-4251-phase-2-trial-with-top-line-results-on-track-for-q4-2019/2476918/Nicox SA announced that it has completed enrollment in its multicenter, dose escalating, US phase 2 clinical trial evaluating the safety and tolerability of NCX 4251 in acute exacerbations of blepharitis. The primary objective of this
- OcuNexus Therapeutics Making Progress with Inflammasome Inhibition Program in Ophthalmic Diseasehttps://modernod.com/news/ocunexus-therapeutics-making-significant-progress-with-inflammasome-inhibition-program-in-ophthalmic-disease/2479550/OcuNexus Therapeutics announced that it has strengthened its board of directors with the addition of Rajiv Shukla, who has deep experience in the investment and commercial aspects of the pharmaceutical industry. OcuNexus Therapeutics is a clinical stage biotechnology company develop
- Promedica International and Dr. Agarwal’s Eye Hospitals Form Strategic Alliancehttps://modernod.com/news/promedica-international-and-dr-agarwals-eye-hospitals-form-strategic-alliance/2476696/Promedica International (PMI) and Dr. Agarwal’s Eye Hospitals (AEH) have formed a new partnership to conduct clinical trials in India, which they announced at the OCTANe Ophthalmology Technology Summit. PMI and AEH em
- Drusen Characteristics Linked With AMD Risk in Fellow Eyeshttps://modernod.com/news/drusen-characteristics-linked-with-amd-risk-in-fellow-eyes/2476571/In patients with unilateral neovascular age-related macular degeneration (AMD), certain drusen features are associated with conversion to neovascular AMD in the fellow eye, according to a secondary analysis of data from a clinical trial, as re
- Schwind Introduces WiseNET Intelligent Web-Based Databasehttps://modernod.com/news/schwind-introduces-wisenet-intelligent-web-based-database/2476554/Schwind WiseNET is a web-based database that allows the user to capture and evaluate refractive treatment data quickly and precisely, and present it graphically for all sorts of uses in daily clinical work. Diagrams s
- New Data from Phase 3 Teprotumumab Trial Shows Reduction in Proptosis, or Eye Bulging, in Active Thyroid Eye Disease (TED)https://modernod.com/news/new-data-from-phase-3-teprotumumab-trial-shows-reduction-in-proptosis-or-eye-bulging-in-active-thyroid-eye-disease-ted/2476506/Horizon Pharma announced that new data from the phase 3 confirmatory clinical trial (OPTIC) evaluating the investigational medicine teprotumumab for the treatment of active thyroid eye disease (TED) were presented
- US Military Develops Mobile Application to Treat Eye Injurieshttps://modernod.com/news/us-military-develops-mobile-application-to-treat-eye-injuries/2476479/The U.S. military medical researchers are developing a mobile application to connect combat medics with on-call ophthalmologists either in-theater or at a clinic to treat eye injuries of soldiers in the field, according to a
- Aldeyra Therapeutics to Present Phase 2b Dry Eye Disease Results at ARVOhttps://modernod.com/news/aldeyra-therapeutics-to-present-phase-2b-dry-eye-disease-results-at-arvo/2476456/Aldeyra Therapeutics announced that John Sheppard, MD, Professor of Ophthalmology at Eastern Virginia Medical School, will present results of the phase 2b clinical trial of topical reproxalap in dry eye disea
- Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitishttps://modernod.com/news/nicox-initiates-phase-2-trial-of-ncx-4251-in-blepharitis/2476393/Nicox SA announced the initiation of a phase 2 clinical trial evaluating NCX 4251, its novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the first targeted topical treatm